PI3K mutations in breast cancer: prognostic and therapeutic implications
Toru MukoharaCancer Center and Division of Medical Oncology/Hematology, Kobe University Hospital, Kobe, JapanAbstract: The PI3K pathway is the most frequently enhanced oncogenic pathway in breast cancer. Among mechanisms of PI3K enhancement, PIK3CA mutations are most frequently (~30%) observed, alon...
Saved in:
Main Author: | Mukohara T |
---|---|
Format: | article |
Language: | EN |
Published: |
Dove Medical Press
2015
|
Subjects: | |
Online Access: | https://doaj.org/article/3fd2933d14fe461bb213d49ef70aed6c |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Dual PI3K and Wnt pathway inhibition is a synergistic combination against triple negative breast cancer
by: Jeffrey P. Solzak, et al.
Published: (2017) -
Synergistic antitumor activity of pan-PI3K inhibition and immune checkpoint blockade in bladder cancer
by: Guru Sonpavde, et al.
Published: (2021) -
SOX4 and SMARCA4 cooperatively regulate PI3k signaling through transcriptional activation of TGFBR2
by: Gaurav A. Mehta, et al.
Published: (2021) -
Anticancer Activity of New Na(I) Complex on Retinoblastoma Cells via Inhibiting PI3K/AKT/mTOR Pathway
by: Jun Zhang, et al.
Published: (2021) -
Abemaciclib as initial therapy for advanced breast cancer: MONARCH 3 updated results in prognostic subgroups
by: Stephen Johnston, et al.
Published: (2021)